Costs of nosocomial pneumonia caused by meticillin-resistant Staphylococcus aureus

E, Ott; Bange, Franz; Reichardt, Christiane; Graf, Karolin; Eckstein, Max L.; Schwab, Frank J.; Chaberny, Iris F.

doi:10.1016/j.jhin.2010.07.007

Cited by 47 publications

(33 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, documented increases in community-acquired MRSA (CA-MRSA) over the last decade has resulted in increasing methicillin resistance rates within community-acquired pneumonia (CAP) [13]. The increase in methicillin resistance within the community has led to a national increase in MRSA rates in early VAP and associated healthcare expenditures [14,15]. The purpose of this study was to evaluate the incidence and trend of early MRSA VAP over a 6-y period in our Level 1 trauma center and to examine the adequacy of our current empiric antibiotic regimen.…”

mentioning

confidence: 99%

Methicillin-ResistantStaphylococcus aureusin Early Ventilator-Associated Pneumonia: Cause for Concern?

Hill

Schroeppel

Magnotti

et al. 2013

Surgical Infections

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Methicillin-ResistantStaphylococcus aureusin Early Ventilator-Associated Pneumonia: Cause for Concern?

Hill

Schroeppel

Magnotti

et al. 2013

Surgical Infections

View full text Add to dashboard Cite

show abstract

“…Sin embargo, Cocanour si encontró un costo promedio de NAV más alto que el estimado en la presente investigación siendo de US$ 82.195 23 . La gran variabilidad encontrada en el costo promedio total de la NAV quizás se deba a la resistencia de algunas bacterias como el S. aureus a antibióticos como la meticilina que incrementa significativamente los costos 24 .…”

Section: Discussionunclassified

Costos de neumonia nosocomial en una unidad de cuidados intensivos en Cartagena, Colombia.

Sanmartin-Ávila¹,

Alvis-Estrada

Valle-Archibold

et al. 2017

Infect

View full text Add to dashboard Cite

Cómo citar este artículo: A. Sanmartin-Ávila, et al. Costos de neumonia nosocomial en una unidad de cuidados intensivos en Cartagena, Colombia. Infectio 2018; 22(1): [13][14][15][16][17][18] Resumen Objetivo: Estimar el exceso de costos directos de atención atribuible a la neumonía asociada a ventilador mecánico en una unidad de cuidados intensivos de adultos en la ciudad de Cartagena durante los años 2009 al 2014. Material y Método: Se plantea un estudio de evaluación económica parcial centrado en el análisis de costos directos de atención contrastando los escenarios de neumonía asociada a ventilador mecánico versus los escenarios sin neumonía asociada a ventilador mecánico. La población de estudio la constituye 23 pacientes con neumonía asociada a ventilador mecánico. Del mismo modo, se tomaron 46 controles. La información correspondiente a los costos directos se obtuvo a través del departamento de costos de la institución hospitalaria. Se estimó la razón de costos que permite establecer el exceso de costo atribuible a la enfermedad nosocomial. Resultados: La estancia promedio en los casos fue de 47 días mientras que en los controles fue de 9 días. El costo promedio de un caso de neumonía asociada a ventilador mecánico fue de US$ 44.354 mientras que el de un control fue de US$ 5.037. Discusión: El exceso de costo promedio total así como el incurrido en antibióticos y en estancia resultan ser mucho más altos que los encontrados en otros estudios realizados. Conclusiones: Un caso de neumonía asociada a ventilador mecánico cuesta 10 veces más con respecto a los medicamentos y 8 veces más con relación a exámenes de laboratorios e insumos. La estancia resulta ser 6,6 veces más costosa que cuando no se presenta esta patología. El costo que se asume en antibióticos es 7,8 veces más alto. Los casos de neumonía asociada a ventilador mecánico cuestan en promedio 8,8 veces más que los controles. Costs of pneumonia nosocomial in a unit of intensive care in Cartagena, Colombia. Palabras claves AbstractAims: To estimate the excess direct care costs attributable to ventilator-associated pneumonia in an intensive care unit adult in the city of Cartagena during the years 2009 to 2014. Material and method: A study of partial economic evaluation focused on the analysis of direct care costs contrasting the scenarios of mechanical ventilator associated pneumonia versus scenarios without mechanical ventilator associated pneumonia. The study population is 23 patients with ventilator associated pneumonia. Similarly, 46 control were taken. The information for direct costs was obtained through the cost department of the hospital institution. The ratio of costs for establishing the excess cost attributable to ventilator associated pneumonia was estimated. Results: The average stay in cases was 47 days, while in controls was 9 days. The average cost of a case of ventilator associated pneumonia was US$ 44354 while the control was US$ 5037. Discussion: Excess average total cost incurred as well as antibiotics and stay out to be much higher...

show abstract

“…Dagegen bleibt der Begriff "Qualität" neutral (Grad, in dem Anforderungen erfüllt werden [26] [27]. In einer Case-Control-Studie wurden die zusätzlichen Kosten einer nosokomialen Pneumonie durch MRSA auf über 17.000 € beziffert, interessanterweise um 5000 € höher liegend als eine Pneumonie durch Methicillin-sensible Staphylokokken [28]. Eine amerikanische Studie zu unerwünschten Arzneimittelereignissen (Analyse von Patientenakten) erbrachte zusätzliche Kosten für vermeidbare Ereignisse von $3500 pro Fall bzw.…”

Section: Qualitätsperspektiveunclassified

Patientensicherheit

Schrappe

2014

Bundesgesundheitsbl.

View full text Add to dashboard Cite

Almost 10 years ago, the German Coalition for Patient Safety (Aktionsbündnis Patientensicherheit) was founded as a cooperation covering most institutions of the German health care system. As in other countries facing the issue of patient safety, methods for the analysis of "never events" have been developed, instruments for the identification of the "unknown unknowns" have been established (e.g., CIRS), and the paradigm of individual blame has been replaced by organizational, team and management factors. After these first steps, further developments can only be achieved in so far as patient safety is understood as a system property, which leads to specific implications for the further evolution of the healthccare system. The "patient safety movement" has to participate in this discussion in order to avoid misuse of the patient safety concept as a defensive means, merely confined to overcome the adverse events of payment and structural incentives (e.g., diagnosis related groups in the inpatient sector). Because the dominant requirements for the future healthcare system consist of care for an elderly population with chronic and multiple diseases, the focus has to be shifted away from acute and surgical procedures and diseases, as given in the present quality assurance programs in Germany, to prevention and coordination of chronic care. Efforts to improve drug and medication safety of elderly people can be regarded as perfect examples, but other efforts are still missing. Second, the structural problems as the sector-associated optimization of care should be addressed, because typical safety issues are not limited to single sectors but represent problems of missing integration and suboptimal population care (e.g., MRSA). In the third line, the perspectives of society and institutions on safety (and quality of care) must urgently be enlarged to the perspectives of patients on the one hand and the benefit of treatments (e.g., overuse) on the other hand. All these issues are only to be implemented as far as the general societal attitude supportings further improvement of patient safety and is ready to regard it as a major aim for future developments. Cost arguments alone - costs of suboptimal safety can be estimated to around 1 billion in Germany per year - are considered as insufficient to guarantee further improvements because other issues in the healthcare system show similar magnitudes. As a consequence, ethical implications remain as major arguments for ongoing professional and public discussions.

show abstract

Costs of nosocomial pneumonia caused by meticillin-resistant Staphylococcus aureus

Cited by 47 publications

References 23 publications

Methicillin-ResistantStaphylococcus aureusin Early Ventilator-Associated Pneumonia: Cause for Concern?

Methicillin-ResistantStaphylococcus aureusin Early Ventilator-Associated Pneumonia: Cause for Concern?

Costos de neumonia nosocomial en una unidad de cuidados intensivos en Cartagena, Colombia.

Patientensicherheit

Contact Info

Product

Resources

About